Top 5 Stocks to Buy Now
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free HRMY Stock Alerts

Harmony Biosciences (HRMY) Competitors

Harmony Biosciences logo
$34.45 +0.29 (+0.85%)
Closing price 06/24/2026 04:00 PM Eastern
Extended Trading
$34.46 +0.00 (+0.01%)
As of 06/24/2026 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HRMY vs. ABVX, QGEN, TGTX, IBRX, and PRAX

Should you buy Harmony Biosciences stock or one of its competitors? MarketBeat compares Harmony Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Harmony Biosciences include Abivax (ABVX), Qiagen (QGEN), TG Therapeutics (TGTX), ImmunityBio (IBRX), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Harmony Biosciences compare to Abivax?

Harmony Biosciences (NASDAQ:HRMY) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Harmony Biosciences has a net margin of 16.20% compared to Abivax's net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
Harmony Biosciences16.20% 17.19% 11.99%
Abivax N/A -99.02%-70.26%

In the previous week, Abivax had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 2 mentions for Abivax and 0 mentions for Harmony Biosciences. Abivax's average media sentiment score of 0.31 beat Harmony Biosciences' score of 0.00 indicating that Abivax is being referred to more favorably in the news media.

Company Overall Sentiment
Harmony Biosciences Neutral
Abivax Neutral

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Harmony Biosciences has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony Biosciences$868.45M2.30$158.69M$2.4813.89
AbivaxN/AN/A-$380.27M-$5.21N/A

Harmony Biosciences presently has a consensus price target of $40.89, indicating a potential upside of 18.69%. Abivax has a consensus price target of $130.08, indicating a potential upside of 40.61%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27
Abivax
1 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.73

Harmony Biosciences has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Abivax has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Summary

Harmony Biosciences beats Abivax on 10 of the 15 factors compared between the two stocks.

How does Harmony Biosciences compare to Qiagen?

Harmony Biosciences (NASDAQ:HRMY) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Qiagen has a net margin of 19.16% compared to Harmony Biosciences' net margin of 16.20%. Harmony Biosciences' return on equity of 17.19% beat Qiagen's return on equity.

Company Net Margins Return on Equity Return on Assets
Harmony Biosciences16.20% 17.19% 11.99%
Qiagen 19.16%14.40%8.40%

In the previous week, Qiagen had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 3 mentions for Qiagen and 0 mentions for Harmony Biosciences. Qiagen's average media sentiment score of 0.37 beat Harmony Biosciences' score of 0.00 indicating that Qiagen is being referred to more favorably in the news media.

Company Overall Sentiment
Harmony Biosciences Neutral
Qiagen Neutral

Harmony Biosciences presently has a consensus price target of $40.89, indicating a potential upside of 18.69%. Qiagen has a consensus price target of $44.71, indicating a potential upside of 15.38%. Given Harmony Biosciences' higher probable upside, equities research analysts clearly believe Harmony Biosciences is more favorable than Qiagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27
Qiagen
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.46

Qiagen has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony Biosciences$868.45M2.30$158.69M$2.4813.89
Qiagen$2.09B3.82$424.88M$1.9120.29

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Harmony Biosciences has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Summary

Qiagen beats Harmony Biosciences on 10 of the 17 factors compared between the two stocks.

How does Harmony Biosciences compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

TG Therapeutics currently has a consensus price target of $58.60, suggesting a potential upside of 9.33%. Harmony Biosciences has a consensus price target of $40.89, suggesting a potential upside of 18.69%. Given Harmony Biosciences' higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.75
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27

TG Therapeutics has a net margin of 65.95% compared to Harmony Biosciences' net margin of 16.20%. TG Therapeutics' return on equity of 88.73% beat Harmony Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics65.95% 88.73% 43.44%
Harmony Biosciences 16.20%17.19%11.99%

In the previous week, TG Therapeutics had 4 more articles in the media than Harmony Biosciences. MarketBeat recorded 4 mentions for TG Therapeutics and 0 mentions for Harmony Biosciences. TG Therapeutics' average media sentiment score of 0.92 beat Harmony Biosciences' score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
TG Therapeutics Positive
Harmony Biosciences Neutral

TG Therapeutics has higher earnings, but lower revenue than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M13.31$447.18M$2.8618.74
Harmony Biosciences$868.45M2.30$158.69M$2.4813.89

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Summary

TG Therapeutics beats Harmony Biosciences on 12 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Harmony Biosciences has a net margin of 16.20% compared to ImmunityBio's net margin of -606.15%. Harmony Biosciences' return on equity of 17.19% beat ImmunityBio's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-606.15% N/A -59.53%
Harmony Biosciences 16.20%17.19%11.99%

ImmunityBio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

ImmunityBio presently has a consensus target price of $14.20, indicating a potential upside of 82.05%. Harmony Biosciences has a consensus target price of $40.89, indicating a potential upside of 18.69%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities research analysts plainly believe ImmunityBio is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27

Harmony Biosciences has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$113.29M72.11-$351.40M-$0.85N/A
Harmony Biosciences$868.45M2.30$158.69M$2.4813.89

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ImmunityBio had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 2 mentions for ImmunityBio and 0 mentions for Harmony Biosciences. ImmunityBio's average media sentiment score of 0.07 beat Harmony Biosciences' score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media.

Company Overall Sentiment
ImmunityBio Neutral
Harmony Biosciences Neutral

Summary

Harmony Biosciences beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does Harmony Biosciences compare to Praxis Precision Medicines?

Harmony Biosciences (NASDAQ:HRMY) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Harmony Biosciences has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony Biosciences$868.45M2.30$158.69M$2.4813.89
Praxis Precision Medicines$8.55M1,007.40-$303.27M-$13.37N/A

Harmony Biosciences presently has a consensus price target of $40.89, suggesting a potential upside of 18.69%. Praxis Precision Medicines has a consensus price target of $566.21, suggesting a potential upside of 83.28%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Harmony Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harmony Biosciences
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
4 Strong Buy rating(s)
2.95

Harmony Biosciences has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market.

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Praxis Precision Medicines had 9 more articles in the media than Harmony Biosciences. MarketBeat recorded 9 mentions for Praxis Precision Medicines and 0 mentions for Harmony Biosciences. Praxis Precision Medicines' average media sentiment score of 0.66 beat Harmony Biosciences' score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company Overall Sentiment
Harmony Biosciences Neutral
Praxis Precision Medicines Positive

Harmony Biosciences has a net margin of 16.20% compared to Praxis Precision Medicines' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Harmony Biosciences16.20% 17.19% 11.99%
Praxis Precision Medicines N/A -43.02%-40.22%

Summary

Harmony Biosciences beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

Get Harmony Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HRMY vs. The Competition

Export
MetricHarmony BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.98B$3.49B$6.74B$12.32B
Dividend YieldN/A2.28%2.68%5.88%
P/E Ratio13.8920.5025.3923.96
Price / Sales2.30328.65530.17107.90
Price / Cash10.74130.9645.2953.76
Price / Book2.288.2610.766.41
Net Income$158.69M$23.91M$3.56B$337.14M
7 Day Performance3.52%2.12%0.98%-1.06%
1 Month Performance14.26%2.40%0.78%0.49%
1 Year Performance9.12%57.09%30.24%28.43%

Harmony Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HRMY
Harmony Biosciences
4.0343 of 5 stars		$34.45
+0.8%		$40.89
+18.7%		+7.5%$1.98B$868.45M13.89200
ABVX
Abivax
3.1776 of 5 stars		$98.26
+1.8%		$130.08
+32.4%		+1,291.1%$7.70BN/AN/A61
QGEN
Qiagen
4.4402 of 5 stars		$36.97
-0.3%		$44.98
+21.7%		-22.1%$7.64B$2.09B19.315,654
TGTX
TG Therapeutics
2.8093 of 5 stars		$50.30
+1.6%		$52.50
+4.4%		+43.7%$7.58B$616.29M17.59290
IBRX
ImmunityBio
3.103 of 5 stars		$7.13
+0.4%		$14.20
+99.2%		+179.6%$7.44B$113.29MN/A590

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HRMY) was last updated on 6/25/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel